BiotechTube
Home/XyloCor Therapeutics/John Tucker
JT

John Tucker

President and Chief Executive Officer

XyloCor Therapeutics

Therapeutic Areas

Cardiovascular DiseaseCoronary Artery Disease

XyloCor Therapeutics Pipeline

DrugIndicationPhase
XC001 (encoberminogene rezmadenovec)Refractory angina due to advanced coronary artery diseasePhase 2